Peripheral Blood Stem Cell Mobilization Tactics

Rosenbeck, Lindsay; Srivastava, Shivani; Kiel, Patrick J.

doi:10.1345/aph.1m289

Cited by 23 publications

(26 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…G-CSF also has a favorable toxicity profile, with the most frequent adverse events being mild to moderate musculoskeletal pain (usually controlled with conventional analgesics), as well as dysuria, fever, headache, nausea and asymptomatic increase in alkaline phosphatase and gamma-glutamyl transferase. 48,49 Retrospective and prospective randomized studies suggest that the granulocyte--monocyte colony stimulating factor (GM-CSF) is less effective than G-CSF in mobilizing hematopoietic progenitor cells, either alone or in combination with chemotherapy, with an additional less favorable profile of safety and tolerability. 48,50 The combination of G-CSF and GM-CSF did not result in significant clinical benefits in comparison with isolated G-CSF.…”

Section: Measurement Of Cd34+ Cell Count In Peripheral Bloodmentioning

confidence: 99%

“…6 The combination of G-CSF with high-doses cyclophosphamide was shown to improve the efficiency of collection and increase the correlation between the CD34+ cell counts in peripheral blood and in the final collection. 8,49 Etoposide, in turn, has shown to be effective in the treatment of Hodgkin's and non-Hodgkin's lymphoma; thus, its inclusion in the mobilization regimens of patients with these tumors has the advantage of providing treatment during the mobilization phase 49 . The combination of vinorelbine and G-CSF is an excellent alternative in comparison with G-CSF alone or in combination with cyclophosphamide, showing a more favorable toxicity profile, resulting in earlier collection and lower costs.…”

Section: Measurement Of Cd34+ Cell Count In Peripheral Bloodmentioning

confidence: 99%

See 1 more Smart Citation

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

Duarte

Prado²,

Vieira

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY Selected patients with certain hematological malignancies and solid tumors have the potential to achieve long-term survival with autologous hematopoietic progenitor cell transplant. The collection of these cells in peripheral blood avoids multiple bone marrow aspirations, results in faster engraftment and allows treatment of patients with infection, fibrosis, or bone marrow hypocellularity. However, for the procedure to be successful, it is essential to mobilize a sufficient number of progenitor cells from the bone marrow into the blood circulation. Therefore, a group of Brazilian experts met in order to develop recommendations for mobilization strategies adapted to the reality of the Brazilian national health system, which could help minimize the risk of failure, reduce toxicity and improve the allocation of financial resources.

show abstract

Section: Measurement Of Cd34+ Cell Count In Peripheral Bloodmentioning

confidence: 99%

Section: Measurement Of Cd34+ Cell Count In Peripheral Bloodmentioning

confidence: 99%

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

Duarte

Prado²,

Vieira

et al. 2016

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…In a recently reported retrospective study of 2177 patients diagnosed with onco-hematological diseases, up to 60% of patients did not mobilize enough HSPC for an autologous transplant procedure [43]. Based on a review of clinical trials using chemotherapy, cytokines or combination regimens for mobilization of HSPC it was concluded that the optimal mobilization strategy is still unknown [41]. Thus, improving the strategies to boost HSPC mobilization could result in better transplantation outcomes.…”

Section: Mobilizationmentioning

confidence: 99%

“…Granulocytecolony stimulating factor (G-CSF, Filgrastim) and granulocyte macrophage (GM)-CSF (Sargramostim) are currently the only cytokines approved by the Food and Drug Administration (FDA) for HSPC mobilization, with G-CSF being the standard of care for initial mobilization therapy [40, 41]. HSPC from G-CSF-mobilized peripheral blood (mPB) engraft better than those from BM or umbilical cord blood (CB) and with fewer adverse reactions.…”

Section: Mobilizationmentioning

confidence: 99%

The Ins and Outs of Hematopoietic Stem Cells: Studies to Improve Transplantation Outcomes

Marquez‐Curtis

Turner

Sridharan

et al. 2010

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Deciphering the mechanisms of hematopoietic stem/progenitor cell (HSPC) mobilization and homing is important for the development of strategies to enhance the efficacy of HSPC transplantation and achieve the full potential of HSPC-based cellular therapy. Investigation of these mechanisms has revealed interdependence among the various molecules, pathways and cellular components involved, and underscored the complex nature of these two processes. This review summarizes recent progress in identifying the specific factors implicated in HSPC mobilization and homing, with emphasis on our own work. Particularly, we will discuss our studies on stromal cell-derived factor-1 and its interaction with its receptor CXCR4, proteases (matrix metalloproteinases and carboxypeptidase M), complement proteins (C1q, C3a, C5a, membrane attack complex), sphingosine-1-phosphate, and pharmacologic agents such as the histone deacetylase inhibitor valproic acid and hyaluronic acid.

show abstract

“…The hematopoietic progenitor cells are anchored in the BM by cytokines (such as CXCR4), which interact with SDF-1 (stromal cell derived factor-1, CXCL12) and adhesion molecules (such as very late antigen-1, VLA-1), which interact with vascular cell adhesion molecule-1. 69 During stem cell mobilization by G-CSF, the release of neutrophil proteases and the subsequent formation of a highly proteolytic environment in the BM results in the cleavage of these key molecules (mainly vascular cell adhesion molecule-1 and SDF-1). The interaction of HSCs with different types of stromal cells in the endosteal and endothelial niches not only has an important role in regulating HSC trafficking, but also affects their self-renewal, proliferation and differentiation capacity.…”

Section: Chemokine Axis Mobilizationmentioning

confidence: 99%

Novel agents and approaches for stem cell mobilization in normal donors and patients

Bakanay

Demirer

2011

Bone Marrow Transplant

View full text Add to dashboard Cite

In spite of the safety and efficiency of the classical mobilization protocols, recombinant human G-CSF ± chemotherapy, there is still a considerable amount of mobilization failures (10--30%), which warrant novel agents and approaches both in an autologous and an allogeneic transplant setting. Attempts to improve CD34 þ yields by using several cytokines and growth factors as adjuncts to G-CSF could not change the standard approaches during the last decade, either because of inefficiency or the adverse events encountered with these agents. As a long-acting G-CSF analog, pegfilgrastim has the advantages of an earlier start of apheresis, reduction in the number of apheresis procedures as well as a reduced number of injections as compared with unconjugated G-CSF. However, dosing and cost-effectiveness especially in cytokine-only mobilizations require further investigation. As interactions between hematopoietic stem cells and the BM microenvironment are better understood, new molecules targeting these interactions are emerging. Plerixafor, which started its journey as an anti-HIV drug, recently ended up being a popular stem cell mobilizer with the ability of rapid mobilization and gained approval as an adjunct to G-CSF for poor mobilizers. At present, it is challenging to search for the best approach by using the available drugs with appropriate timing to provide sufficient CD34 þ yield after an initial mobilization attempt, and in a cost-effective manner thereby avoiding further mobilization attempts and exposure to chemotherapy. Approaches not only for increasing stem cell yield, but also aiming to improve the quality of graft content and the associated transplantation outcomes are promising areas of research.

show abstract

Peripheral Blood Stem Cell Mobilization Tactics

Cited by 23 publications

References 72 publications

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations

The Ins and Outs of Hematopoietic Stem Cells: Studies to Improve Transplantation Outcomes

Novel agents and approaches for stem cell mobilization in normal donors and patients

Contact Info

Product

Resources

About